In vitro activities and detection performances of cefmetazole and flomoxef for extended-spectrum β-lactamase and plasmid-mediated AmpC β-lactamase-producing Enterobacteriaceae

Diagnostic Microbiology and Infectious Disease
Yasufumi MatsumuraS Ichiyama

Abstract

To investigate the in vitro activities of cephamycins (cefmetazole and flomoxef) for extended-spectrum β-lactamase (ESBL)- and plasmid-mediated AmpC β-lactamase (pAmpC)-producing Enterobacteriaceae, a total of 574 third-generation cephalosporin-resistant clinical isolates were collected at a Japanese multicenter study. PCR and sequencing identified 394 isolates with only ESBL genes, 63 isolates with only pAmpC genes, and 6 isolates with both ESBL and pAmpC genes. blaCTX-M types predominated 95.5% of the ESBL genes, and blaCMY-2 predominated 91.3% of the pAmpC genes. The MIC50/90 values of cefmetazole and flomoxef were ≤ 1/4 and ≤ 1/≤ 1 μg/mL for isolates with only ESBL genes, respectively, and 16/>16 and 8/16 μg/mL for isolates with only pAmpC genes, respectively. Flomoxef ≥ 4 μg/mL had the best screening performance for the detection of isolates with pAmpC genes. Flomoxef had better in vitro activities against ESBL-producing Enterobacteriaceae and provided a clearer distinction between ESBL and pAmpC-producing Enterobacteriaceae compared to cefmetazole.

References

Jul 4, 2002·The Journal of Antimicrobial Chemotherapy·Frédéric BertNicole Lambert-Zechovsky
Nov 10, 2005·Journal of Medical Microbiology·Li XuPeter Hawkey
Feb 23, 2008·The Lancet Infectious Diseases·Johann D D Pitout, Kevin B Laupland
Jun 6, 2009·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Khetam HusseinRenato Finkelstein
Aug 19, 2009·The Journal of Antimicrobial Chemotherapy·Peter M Hawkey, Annie M Jones
Nov 18, 2010·The Journal of Antimicrobial Chemotherapy·Benjamin A RogersDavid L Paterson
Jun 3, 2011·Journal of Clinical Microbiology·Silke PolsfussMichael Hombach
Jan 24, 2012·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·S PolsfussM Hombach
Jan 3, 2013·International Journal of Antimicrobial Agents·Elise WillemsReinoud Cartuyvels
Mar 16, 2013·International Journal of Medical Microbiology : IJMM·Marco Maria D'AndreaGian Maria Rossolini
Mar 26, 2013·Diagnostic Microbiology and Infectious Disease·Helio S SaderRonald N Jones
Feb 18, 2015·The Journal of Antimicrobial Chemotherapy·Yasufumi MatsumuraUNKNOWN Kyoto-Shiga Clinical Microbiology Study Group

❮ Previous
Next ❯

Citations

Jan 13, 2017·The Journal of Antimicrobial Chemotherapy·Yasufumi MatsumuraUNKNOWN 89th JAID BRG
Aug 2, 2019·Current Opinion in Critical Care·Carlota GudiolJordi Carratalà
Nov 14, 2019·Expert Review of Anti-infective Therapy·Abdullah Tarık Aslan, Murat Akova
Apr 1, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Pranita D Tamma, Jesus Rodriguez-Bano
Aug 6, 2021·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Yukihiro HamadaKayoko Hayakawa
Dec 31, 2021·The Journal of Antimicrobial Chemotherapy·Christopher A Darlow, William Hope

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.